Do analysts prefer FBLG or IMCC?

FibroBiologics currently has a consensus target price of $74.00, suggesting a potential upside of 8,065.07%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts clearly believe FibroBiologics is more favorable than IM Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FBLG or IMCC more profitable?

FibroBiologics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% IM Cannabis -27.65% -585.96% -39.96%

Does the media favor FBLG or IMCC?

In the previous week, FibroBiologics had 3 more articles in the media than IM Cannabis. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat FibroBiologics' score of 0.50 indicating that IM Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate SPRC or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SPRC or IMCC?

IM Cannabis has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.41 -$12.18M N/A N/A IM Cannabis $39.17M 0.02 -$8.10M -$1.75 N/A

Is SPRC or IMCC more profitable?

SciSparc has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. SciSparc's return on equity of 0.00% beat IM Cannabis' return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A IM Cannabis -27.65% -585.96% -39.96%

Does the media favor SPRC or IMCC?

In the previous week, SciSparc had 1 more articles in the media than IM Cannabis. MarketBeat recorded 3 mentions for SciSparc and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat SciSparc's score of 0.96 indicating that IM Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer BGMS or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BGMS or IMCC?

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than IM Cannabis. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat Cyclacel Pharmaceuticals' score of 0.29 indicating that IM Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclacel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate CUPR or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CUPR or IMCC?

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than IM Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $40K 137.08 -$3.63M N/A N/A IM Cannabis $39.17M 0.02 -$8.10M -$1.75 N/A

Does the media refer more to CUPR or IMCC?

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than IM Cannabis. MarketBeat recorded 3 mentions for Cuprina Holdings (Cayman) and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat Cuprina Holdings (Cayman)'s score of 0.49 indicating that IM Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cuprina Holdings (Cayman) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IM Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer CAPS or IMCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

IM Cannabis (IMCC) Competitors

$0.16 -0.01 (-7.90%)

Closing price 04:00 PM Eastern

Extended Trading

$0.16 +0.00 (+0.58%)

As of 07:56 PM Eastern

Compare

IMCC vs. FBLG, SPRC, BGMS, CUPR, and CAPS

Should you buy IM Cannabis stock or one of its competitors? MarketBeat compares IM Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IM Cannabis include FibroBiologics (FBLG), SciSparc (SPRC), Cyclacel Pharmaceuticals (BGMS), Cuprina Holdings (Cayman) (CUPR), and Capstone Therapeutics (CAPS). These companies are all part of the "pharmaceutical products" industry.

How does IM Cannabis compare to FibroBiologics?

FibroBiologics (NASDAQ:FBLG) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

7.7% of IM Cannabis shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

FibroBiologics currently has a consensus target price of $74.00, suggesting a potential upside of 8,065.07%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts clearly believe FibroBiologics is more favorable than IM Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FibroBiologics has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. IM Cannabis' return on equity of -585.96% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
IM Cannabis	-27.65%	-585.96%	-39.96%

IM Cannabis has higher revenue and earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

FibroBiologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

In the previous week, FibroBiologics had 3 more articles in the media than IM Cannabis. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat FibroBiologics' score of 0.50 indicating that IM Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

IM Cannabis beats FibroBiologics on 9 of the 15 factors compared between the two stocks.

How does IM Cannabis compare to SciSparc?

SciSparc (NASDAQ:SPRC) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

SciSparc has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. SciSparc's return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
IM Cannabis	-27.65%	-585.96%	-39.96%

25.1% of SciSparc shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 1.5% of SciSparc shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SciSparc has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

In the previous week, SciSparc had 1 more articles in the media than IM Cannabis. MarketBeat recorded 3 mentions for SciSparc and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat SciSparc's score of 0.96 indicating that IM Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IM Cannabis has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.41	-$12.18M	N/A	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

Summary

SciSparc beats IM Cannabis on 7 of the 11 factors compared between the two stocks.

How does IM Cannabis compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and IM Cannabis (NASDAQ:IMCC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Cyclacel Pharmaceuticals' return on equity of -51.21% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
IM Cannabis	-27.65%	-585.96%	-39.96%

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than IM Cannabis. MarketBeat recorded 3 mentions for Cyclacel Pharmaceuticals and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat Cyclacel Pharmaceuticals' score of 0.29 indicating that IM Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than IM Cannabis. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	8.10	-$3M	-$4.54	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its stock price is 138% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cyclacel Pharmaceuticals beats IM Cannabis on 7 of the 13 factors compared between the two stocks.

How does IM Cannabis compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and IM Cannabis (NASDAQ:IMCC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Cuprina Holdings (Cayman) has a beta of -1.2, meaning that its stock price is 220% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than IM Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$40K	137.08	-$3.63M	N/A	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to IM Cannabis' net margin of -27.65%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
IM Cannabis	-27.65%	-585.96%	-39.96%

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than IM Cannabis. MarketBeat recorded 3 mentions for Cuprina Holdings (Cayman) and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.89 beat Cuprina Holdings (Cayman)'s score of 0.49 indicating that IM Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cuprina Holdings (Cayman)	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IM Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

7.7% of IM Cannabis shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cuprina Holdings (Cayman) beats IM Cannabis on 6 of the 11 factors compared between the two stocks.

How does IM Cannabis compare to Capstone Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IM Cannabis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IM Cannabis has a net margin of -27.65% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat IM Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-41.26%	-114.15%	-39.74%
IM Cannabis	-27.65%	-585.96%	-39.96%

In the previous week, IM Cannabis had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for IM Cannabis and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.89 equaled IM Cannabis'average media sentiment score.

Company	Overall Sentiment
Capstone Therapeutics	Very Positive
IM Cannabis	Very Positive

IM Cannabis has lower revenue, but higher earnings than Capstone Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$48.11M	0.09	-$21.23M	-$3.37	N/A
IM Cannabis	$39.17M	0.02	-$8.10M	-$1.75	N/A

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Capstone Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

Summary

Capstone Therapeutics and IM Cannabis tied by winning 6 of the 12 factors compared between the two stocks.

Get IM Cannabis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCC vs. The Competition

Export

Metric	IM Cannabis	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05M	$8.32B	$6.81B	$12.59B
Dividend Yield	N/A	2.52%	2.67%	6.15%
P/E Ratio	-0.09	15.70	27.67	25.26
Price / Sales	0.02	7.23	533.70	101.14
Price / Cash	N/A	17.65	47.99	59.26
Price / Book	-0.32	3.55	10.96	6.62
Net Income	-$8.10M	$226.25M	$3.57B	$336.83M
7 Day Performance	-3.24%	1.68%	2.58%	2.52%
1 Month Performance	-51.58%	-2.87%	1.67%	0.44%
1 Year Performance	-94.26%	3.97%	35.96%	29.40%

IM Cannabis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCC IM Cannabis	0.6633 of 5 stars	$0.16 -7.9%	N/A	-93.2%	$1.05M	$39.17M	N/A	340	News Coverage Positive News Gap Down
FBLG FibroBiologics	2.5484 of 5 stars	$0.77 +2.5%	$74.00 +9,517.9%	-92.6%	$3.91M	N/A	N/A	10	News Coverage
SPRC SciSparc	1.2949 of 5 stars	$5.86 -15.3%	N/A	-90.6%	$3.91M	$860K	N/A	4	News Coverage Gap Down
BGMS Cyclacel Pharmaceuticals	0.7285 of 5 stars	$0.64 -4.5%	N/A	N/A	$3.68M	$750K	N/A	14
CUPR Cuprina Holdings (Cayman)	0.4124 of 5 stars	$5.74 +45.7%	N/A	N/A	$3.63M	$40K	N/A	14	Short Interest Increase Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCC) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IM Cannabis (IMCC) Competitors

IMCC vs. FBLG, SPRC, BGMS, CUPR, and CAPS

How does IM Cannabis compare to FibroBiologics?

Summary

How does IM Cannabis compare to SciSparc?

Summary

How does IM Cannabis compare to Cyclacel Pharmaceuticals?

Summary

How does IM Cannabis compare to Cuprina Holdings (Cayman)?

Summary

How does IM Cannabis compare to Capstone Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IM Cannabis (IMCC) Competitors

IMCC vs. FBLG, SPRC, BGMS, CUPR, and CAPS

How does IM Cannabis compare to FibroBiologics?

Do insiders and institutionals hold more shares of FBLG or IMCC?

Do analysts prefer FBLG or IMCC?

Is FBLG or IMCC more profitable?

Which has stronger valuation & earnings, FBLG or IMCC?

Which has more volatility and risk, FBLG or IMCC?

Does the media favor FBLG or IMCC?

Summary

How does IM Cannabis compare to SciSparc?

Is SPRC or IMCC more profitable?

Do insiders and institutionals hold more shares of SPRC or IMCC?

Which has more risk & volatility, SPRC or IMCC?

Does the media favor SPRC or IMCC?

Do analysts rate SPRC or IMCC?

Which has higher valuation & earnings, SPRC or IMCC?

Summary

How does IM Cannabis compare to Cyclacel Pharmaceuticals?

Do analysts prefer BGMS or IMCC?

Is BGMS or IMCC more profitable?

Does the media refer more to BGMS or IMCC?

Which has stronger earnings & valuation, BGMS or IMCC?

Which has more volatility and risk, BGMS or IMCC?

Do institutionals & insiders hold more shares of BGMS or IMCC?

Summary

How does IM Cannabis compare to Cuprina Holdings (Cayman)?

Which has more volatility & risk, CUPR or IMCC?

Which has preferable valuation and earnings, CUPR or IMCC?

Do analysts rate CUPR or IMCC?

Is CUPR or IMCC more profitable?

Does the media refer more to CUPR or IMCC?

Do insiders and institutionals believe in CUPR or IMCC?

Summary

How does IM Cannabis compare to Capstone Therapeutics?

Do analysts prefer CAPS or IMCC?

Is CAPS or IMCC more profitable?

Does the media favor CAPS or IMCC?

Which has stronger earnings & valuation, CAPS or IMCC?

Do institutionals and insiders hold more shares of CAPS or IMCC?

Which has more risk and volatility, CAPS or IMCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC vs. The Competition

IM Cannabis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools